Anthrax

$6M contract awarded to develop CpG immunostimulatory TLR9 agonists

Published in Medical Letter on the CDC and FDA, July 27th, 2003

Coley Pharmaceutical Group announced that the U.S. Defense Advanced Research Projects Agency (DARPA) has awarded an additional $6M to Coley to support the clinical development of Coley's CpG immunostimulatory TLR9 agonists to enhance anthrax vaccines.

This brings to $12M the total amount in contracts granted directly to Coley by DARPA in the last 18 months.

The research at Coley stems from an initial $4MM grant awarded in 1999 to Arthur M. Krieg, MD, senior VP and chief scientific officer of Coley, when he was a professor of Internal Medicine at the University of Iowa.

"Since DARPA began supporting the development of our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry